Modulation of the ETV6::RUNX1 Gene Fusion Prevalence in Newborns by Corticosteroid Use During Pregnancy
Por:
Benítez, L, Fischer, U, Crispi, F, Castro-Barquero, S, Crovetto, F, Larroya, M, Youssef, L, Kameri, E, Castillo, H, Bueno, C, Casas, R, Borras, R, Vieta, E, Estruch, R, Menéndez, P, Borkhardt, A and Gratacós, E
Publicada:
25 mar 2025
Ahead of Print:
25 mar 2025
Resumen:
ETV6::RUNX1-positive pediatric acute lymphoblastic leukemia frequently has a prenatal origin and follows a two-hit model: a first somatic alteration leads to the formation of the oncogenic fusion gene ETV6::RUNX1 and the generation of a preleukemic clone in utero. Secondary hits after birth are necessary to convert the preleukemic clone into clinically overt leukemia. However, prenatal factors triggering the first hit have not yet been determined. Here, we explore the influence of maternal factors during pregnancy on the prevalence of the ETV6::RUNX1 fusion. To this end, we employed a nested interventional cohort study (IMPACT-BCN trial), including 1221 pregnancies (randomized into usual care, a Mediterranean diet, or mindfulness-based stress reduction) and determined the prevalence of the fusion gene in the DNA of cord blood samples at delivery (n = 741) using the state-of-the-art GIPFEL (genomic inverse PCR for exploration of ligated breakpoints) technique. A total of 6.5% (n = 48 of 741) of healthy newborns tested positive for ETV6::RUNX1. Our multiple regression analyses showed a trend toward lower ETV6::RUNX1 prevalence in offspring of the high-adherence intervention groups. Strikingly, corticosteroid use for lung maturation during pregnancy was significantly associated with ETV6::RUNX1 (adjusted OR 3.9, 95% CI 1.6-9.8) in 39 neonates, particularly if applied before 26 weeks of gestation (OR 7.7, 95% CI 1.08-50) or if betamethasone (OR 4.0, 95% CI 1.4-11.3) was used. Prenatal exposure to corticosteroids within a critical time window may therefore increase the risk of developing ETV6::RUNX1+ preleukemic clones and potentially leukemia after birth. Taken together, this study indicates that ETV6::RUNX1 preleukemia prevalence may be modulated and potentially prevented.
Filiaciones:
Benítez, L:
Univ Barcelona, Hosp Clin, BCNatal Fetal Med Res Ctr, Barcelona 08950, Spain
Univ Barcelona, Hosp St Joan Deu, Barcelona 08950, Spain
Inst Invest Biomed August Pi i Sunyer, Barcelona 08036, Spain
Fischer, U:
Heinrich Heine Univ, Univ Childrens Hosp, Med Fac, Dept Pediat Oncol Hematol & Clin Immunol, D-40225 Dusseldorf, Germany
German Canc Consortium, Partner Site Essen Dusseldorf, D-40225 Dusseldorf, Germany
Deutsch Krebsforschungszentrum DKFZ, D-69120 Heidelberg, Germany
Crispi, F:
Univ Barcelona, Hosp Clin, BCNatal Fetal Med Res Ctr, Barcelona 08950, Spain
Univ Barcelona, Hosp St Joan Deu, Barcelona 08950, Spain
Inst Invest Biomed August Pi i Sunyer, Barcelona 08036, Spain
Castro-Barquero, S:
Univ Barcelona, Hosp Clin, BCNatal Fetal Med Res Ctr, Barcelona 08950, Spain
Univ Barcelona, Hosp St Joan Deu, Barcelona 08950, Spain
Inst Salud Carlos III ISCII, Red Espanola Terapias Avanzadas, Madrid 28029, Spain
Inst Salud Carlos III ISCIII, Ctr Invest Biomed Red Canc CIBER ONC, Madrid 28029, Spain
Crovetto, F:
Univ Barcelona, Hosp Clin, BCNatal Fetal Med Res Ctr, Barcelona 08950, Spain
Univ Barcelona, Hosp St Joan Deu, Barcelona 08950, Spain
Inst Recerca St Joan Deu, Barcelona 08950, Spain
Larroya, M:
Univ Barcelona, Hosp Clin, BCNatal Fetal Med Res Ctr, Barcelona 08950, Spain
Univ Barcelona, Hosp St Joan Deu, Barcelona 08950, Spain
Inst Invest Biomed August Pi i Sunyer, Barcelona 08036, Spain
:
Univ Barcelona, Hosp Clin, BCNatal Fetal Med Res Ctr, Barcelona 08950, Spain
Univ Barcelona, Hosp St Joan Deu, Barcelona 08950, Spain
Inst Invest Biomed August Pi i Sunyer, Barcelona 08036, Spain
Josep Carreras Leukemia Res Inst, Barcelona 08916, Spain
Kameri, E:
Heinrich Heine Univ, Univ Childrens Hosp, Med Fac, Dept Pediat Oncol Hematol & Clin Immunol, D-40225 Dusseldorf, Germany
Deutsch Krebsforschungszentrum DKFZ, D-69120 Heidelberg, Germany
Castillo, H:
Univ Barcelona, Hosp Clin, BCNatal Fetal Med Res Ctr, Barcelona 08950, Spain
Univ Barcelona, Hosp St Joan Deu, Barcelona 08950, Spain
:
Josep Carreras Leukemia Res Inst, Barcelona 08916, Spain
Univ Barcelona, Sch Med, Dept Biomed, Barcelona 08014, Spain
Inst Catalana Recerca & Estudis Avancats, Barcelona 08010, Spain
Casas, R:
Ctr Invest Biomed Red Fisiopatol Obes & Nutr, Madrid 28029, Spain
Univ Barcelona, Inst Recerca Nutr & Seguretat Alimentaria, Barcelona 08014, Spain
Univ Barcelona, Hosp Clin, Dept Internal Med, Barcelona 08014, Spain
Borras, R:
Univ Barcelona, Hosp Clin, Dept Internal Med, Barcelona 08014, Spain
Vieta, E:
Inst Salud Carlos III, Ctr Invest Biomed Red & Salud Mental, CIBERSAM, Madrid 28029, Spain
Univ Barcelona, Neurosci Inst, Dept Psychiat & Psychol, Hosp Clin,CIBERSAM,IDIBAPS, Barcelona 08014, Spain
Estruch, R:
Univ Barcelona, Sch Med, Dept Biomed, Barcelona 08014, Spain
Inst Catalana Recerca & Estudis Avancats, Barcelona 08010, Spain
Ctr Invest Biomed Red Fisiopatol Obes & Nutr, Madrid 28029, Spain
:
Josep Carreras Leukemia Res Inst, Barcelona 08916, Spain
Univ Barcelona, Sch Med, Dept Biomed, Barcelona 08014, Spain
Inst Catalana Recerca & Estudis Avancats, Barcelona 08010, Spain
Borkhardt, A:
Heinrich Heine Univ, Univ Childrens Hosp, Med Fac, Dept Pediat Oncol Hematol & Clin Immunol, D-40225 Dusseldorf, Germany
German Canc Consortium, Partner Site Essen Dusseldorf, D-40225 Dusseldorf, Germany
Gratacós, E:
Univ Barcelona, Hosp Clin, BCNatal Fetal Med Res Ctr, Barcelona 08950, Spain
Univ Barcelona, Hosp St Joan Deu, Barcelona 08950, Spain
Inst Invest Biomed August Pi i Sunyer, Barcelona 08036, Spain
Inst Recerca St Joan Deu, Barcelona 08950, Spain
Green Submitted, gold
|